Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, includingthe U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activityto be presented at the American Society of Hematology (ASH) 2026 Annual Meeting -- -- Strong financial position with $528.5 million in cash, cash equivalents, and marketable securities as ofSeptember 30, 2026, expected to fund operations into 2H 2029 -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with